Look Towards A New Future

Oct 4, 2010

Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth Market Research Report in its Store.

Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to off-set slowing sales growth in more developed markets.


Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Brazil

Assesses the size of Brazil’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

Examines Brazil’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

Quantifies Brazil’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis


Brazil spent 10.8% of its GDP on both retail and hospital prescribed pharmaceuticals in 2009, reflecting the government’s changing priorities, prioritizing healthcare including initiatives to expand access to medicines.

Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.

Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed for investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, expanding operations, and new product launches.

Reasons to Purchase
  • Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Brazil.
  • Quantify the size and growth of the prescription pharmaceutical market in Brazil, analyzing key therapy areas, brands and companies.
  • Assess drivers and resistors of generic and biosimilars uptake in Brazil.

Original Source : Brazil Pharmaceutical Market

Buy Now : Market Research

Table Of Contents
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global issue reports: 2

1. Brazil – Executive Summary 3
Strategic scoping and focus 3
Key findings – healthcare drivers and resistors in Brazil 4
Key findings – healthcare drivers and resistors in Brazil 4
Brazil – Socio-demographic and economic analysis 7
Socio-demographic trends 7
Socioeconomic trends 8
Brazil – Healthcare system and drug regulatory analysis 11
Brazil healthcare expenditure 11
Brazil healthcare system overview 12
Brazil regulatory issues 13
Brazil pricing and reimbursement issues 13
Brazil – Prescription pharmaceutical sales analysis 15
Pharmaceutical market size 15
Leading therapy areas 15
Leading pharmaceutical brands 15
Leading pharmaceutical companies 15
Brazil – Drug expiry analysis 17
Brazil retail generics market 17
Brazil brand erosion post patent expiry 17
Brazil biosimilars market 17
Brazil – Pharmaceutical Industry Infrastructure analysis 19
Pharmaceutical industry infrastructure overview 19
Related reports 21
Upcoming related reports 21

2. Brazil – Socio-demographic and economic analysis 23
Key findings 23
Socio-demographic trends 23
Socioeconomic trends 23
Demographic trends in Brazil 25
Brazil’s population expected to expand rapidly, peaking in 2040 26
Declining number of births with improving infant mortality rates 28
The Brazilian population is slowly aging 29
The Brazilian population is living longer 30
Disease burden in Brazil 31
Heart disease a leading cause of death in Brazil as in more developed markets 32
Violence and social deprivation still significant despite progress 33
An unexpectedly high rate of prostate cancer deaths representative of gaps in healthcare provision 34
Political climate 35
The end of the Lula government but his legacy will live on 35
The effect of the global economic crisis has been felt less in Brazil 36
PAC gives Brazil much needed infrastructure development 36
Is the Brazilian economy in danger of overheating? 37
Debt reduction a fundamental feature of Lula’s economic policy 38
Increased prosperity has brought income disparities 41
Business environment 41
Setting up business in Brazil can be complex and difficult 41
The Brazilian tax system is complicated and confusing 42
Workforce is extensive but poorly educated 42

3. Brazil – Healthcare system and drug regulatory analysis 44
Key findings 44
Brazil healthcare expenditure 44
Brazil healthcare system overview 44
Brazil regulatory issues 45
Brazil pricing and reimbursement issues 45
Healthcare system 47
Healthcare expenditure in Brazil is rising 47
Growing cost pressures may lead to a cut in the medication budget 49
Healthcare is delivered through two systems 50
The SUS provides universal healthcare coverage in Brazil 51
SUS management has become less centralized 52
Private health insurance system – most Brazilians use the SUS, but the private health segment is expanding 53
Brazil has sought to expand healthcare coverage to reduce inequalities 54
The Family Health Program reduces burden on hospitals and specialist care 54
The Popular Pharmacy program was set up to increase the supply of medicines to the poor 55
Regulatory issues in Brazil 56
Regulatory issues in Brazil 56
Drug approval and regulatory processes – pharma companies regard Brazil’s regulatory environment as unpredictable 56
ANVISA is the national body in charge of regulating medicines in Brazil 56
Similares are being phased out – bioequivalence studies are required for generic drugs in Brazil since 2003 57
Plant inspections are causing lengthy approval times in Brazil 57
ANVISA introduces a new decree on pharmacovigilance 58
Intellectual property protection in Brazil 58
The speed of patent review is slow and backlogs exist 58
There is conflict between the two agencies involved in assessing patent applications 59
There is no set period of data exclusivity in Brazil 59
Compulsory licenses on HIV/AIDS drugs were used only as a threat until May 2007 60
Pipeline patents have awarded several HIV/AIDS drugs extra protections but could be overruled in the future 61
Drug counterfeiting is on the rise in Brazil 61
Drug importation – imported pharmaceuticals have to be registered with ANVISA 62
Pricing and reimbursement in Brazil 63
Pricing issues in Brazil 63
Pricing of new drugs is controlled by the CMED 63
Prices of marketed pharmaceuticals are controlled through price freezes and increases 64
Antiretroviral therapies are priced low in Brazil 65
Reimbursement issues in Brazil – Reimbursable pharmaceuticals are included on the National list of Essential Medicines 66
The Pharmaceutical Care in Primary Healthcare program provides access to essential drugs 67
Strategic program for pharmaceutical assistance includes medicines for neglected diseases 67
The Specialist Pharmaceutical Assistance Component provides specialist and high-cost medicines 68
Despite the SUS reimbursement programs, many patients still do not have access to medicines 68

4. Brazil – Prescription pharmaceutical sales analysis 70
Key findings 70
Pharmaceutical market size 70
Leading therapy areas 70
Leading pharmaceutical brands 70
Leading pharmaceutical companies 70
Pharmaceutical market size in Brazil 72
Leading therapy areas in Brazil 74
Central nervous system was the largest therapy area in terms of sales 76
Musculoskeletal drugs have shown the fastest growth rates 76
Urology and metabolic have shown the slowest growth rates 77
Leading pharmaceutical brands in Brazil 78
Top-selling drug Dorflex sees its franchise extended with follow-up product 81
Cialis to maintain momentum thanks to lifecycle management strategy 81
Lipitor is expected to continue reaching high sales even after patent expiration 81
Leading pharmaceutical companies in Brazil 82
Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley
Novartis’s Brazilian retail sales growth driven by its Diovan franchise 84
The leading domestic companies are exhibiting double-digit growth rates 86
EMS 87
Eurofarma 87
Neo Quimica 88

5. Brazil – Drug expiry analysis 89
Key findings 89
Brazil retail generics market 89
Brazil brand erosion post patent expiry 89
Brazil biosimilars market 89
Brazilian generics market dynamics 91
Similares versus true generics 92
Brazilian generics volume uptake 94
Brazilian generics value uptake 95
Brazilian generics market size 96
Drivers and resistors in the Brazilian generics market 97
Several legislative measures have driven generic uptake 98
Loose patent regulations lead to increased market potential for generic players 99
Market pressures drive down generics prices below the mandatory 35% discount 99
International pressures could hamper generics importers 100
Similares provide affordable healthcare, but bioequivalence legislation has fueled the uptake of true generics 100
Key generics players in the Brazilian market 101
Acquiring local generics players is key strategy for foreign players to penetrate the Brazilian market 102
Sanofi-Aventis extends its dominance in Brazil 103
Pfizer seeks to extend its presence in Brazil 104
Valeant acquires two Brazilian generic drug companies 105
Lupin committed to gaining ground in Brazil 105
Opportunities for the generics industry 106
Small molecule brand erosion in the Brazilian market 107
Number of generic entrants by therapy area 107
Brazil biosimilars market dynamics 108
Drivers and resistors of biosimilar growth in Brazil 108
Rising healthcare costs 108
Biosimilars approval process enacted in 2005 109
Indian-based companies dominate the market 109
New and future biosimilar launches 111
Opportunities for the biosimilar industry 112
Monoclonal antibody therapies could soon face biosimilar incursion in Brazil 113
Biosimilars in development internationally 115

6. Brazil – Pharmaceutical Industry Infrastructure analysis 116
Key findings 116
Pharmaceutical industry infrastructure overview 116
Key company infrastructure in Brazil 117
EMS 118
Novartis 121
Ache Labs 125
Medley 128
Sanofi-Aventis 128
Eurofarma 131
Pfizer 134
Bayer Schering 138
Castro Marques 141
Merck & Co. 143

7. Bibliography 147
Brazil – Executive summary 147
Publications and online articles 147
Brazil – Socio-demographic and economic analysis 148
Publications and online articles 148
Datamonitor reports and products 151
Brazil – Healthcare systems and regulations 151
Publications and online articles 151
Datamonitor reports and products 155
Brazil – Prescription pharmaceutical sales 155
Publications and online articles 155
Brazil – Drug expiry analysis 156
Publications and online articles 156
Datamonitor reports and products 159
Brazil – Pharmaceutical industry infrastructure analysis 160
Publications and online articles 160
Datamonitor reports and products 161

Exchange rates used in this report 162
Datamonitor prescription pharmaceutical definition and therapy area classification 163
About Datamonitor 164
About Datamonitor Healthcare 164
Datamonitor consulting 164
Disclaimer 165
Disclaimer 166

Related Reports:

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004